Increasing Ciliary ARL13B Expression Drives Active and Inhibitor-Resistant SMO and GLI into Glioma Primary Cilia

Abstract

ADP-ribosylation factor-like protein 13B (ARL13B), a regulatory GTPase and guanine exchange factor (GEF) enriches in primary cilia and promotes tumorigenesis in part by regulating Smoothened (SMO), GLI, and Sonic hedgehog (SHH) signaling. Gliomas with increased ARL13B, SMO and GLI2 expression are more aggressive but the relationship to cilia is unclear. Previous studies showed increasing ARL13B in glioblastoma cells promoted ciliary SMO accumulation, independent of exogenous SHH addition. Here we show SMO accumulation is due to increased ciliary, but not extraciliary ARL13B. Increasing ARL13B expression promotes the accumulation of both activated SMO and GLI2 in glioma cilia, but not in NIH3T3 fibroblast cilia. ARL13B-driven increases in ciliary SMO and GLI2 are resistant to SMO inhibitors, GDC-0449 and cyclopamine. Finally, temozolomide chemotherapy which increases ARL13B expression in glioma, stimulates SMO and GLI2 into glioma cilia, but not fibroblast cilia. Collectively, our data suggest factors that elevate ARL13B may drive drug-resistant SMO and GLI into cilia. This suggests the ARL13B-associated mechanism that leads to ciliary SMO/GLI recruitment may promote treatment resistance in glioma.